In overexpressing PRMT6 cells, Olaparib treatment reduced the proliferation and invasive ability of breast cancer cells compared with the control group, whereas PER3 deletion rescued these effects (Figure 7F–H). Here, PRMT6 is linked to breast carcinoma.